fluphenazine and Acute Disease studies

Research Excerpts

Excerpt	Relevance	Reference
"Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia."	9.09	Diazepam treatment of early signs of exacerbation in schizophrenia. ( Breier, AF; Buchanan, RW; Carpenter, WT; Kirkpatrick, B, 1999)
"/day) versus fixed standard dosage (20 mg."	6.64	High vs standard dosage fluphenazine HCL in acute schizophrenia. ( Donlon, PT; Meadow, A; Tupin, JP; Wahba, M, 1978)
" The clinical effectivity came up to the usual therapy with normal high dosage after 28 days therapy, a somewhat more rapid deliverance of symptoms during the first days remained impressive."	5.26	High dosage treatment with fluphenazine intravenously followed by depot injections in acute schizophrenia. ( Fleischhauer, J, 1980)
"Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia."	5.09	Diazepam treatment of early signs of exacerbation in schizophrenia. ( Breier, AF; Buchanan, RW; Carpenter, WT; Kirkpatrick, B, 1999)
"Fifty-three patients with acute exacerbations of Research Diagnostic Criteria schizophrenic, schizoaffective (mainly schizophrenic), and other nonaffective psychoses completed 24 or 28 days of treatment with randomized, fixed, double-blind doses of 10, 20, or 30 mg of oral fluphenazine hydrochloride daily."	5.06	Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. ( Jain, A; Levinson, DF; Silver, P; Simpson, GM; Singh, H; Stephanos, MJ; Yadalam, K, 1990)
"Oral fluphenazine was given in fixed, randomized, double-blind doses (10, 20, or 30 mg/day) for 4 weeks to 72 inpatients with acute schizophrenic exacerbations."	2.68	Fluphenazine plasma levels, dosage, efficacy, and side effects. ( Cooper, TB; Levinson, DF; Lo, ES; Simpson, GM; Singh, H; Stephanos, MJ; Yadalam, K, 1995)
" The 44 patients in this study were randomly assigned to the psychotherapy condition and to either a high or low dosage of phenothiazines."	2.65	Therapist ratings of achievement of objectives in psychotherapy with acute schizophrenics. ( Goldstein, MJ; King, CE, 1979)
"/day) versus fixed standard dosage (20 mg."	2.64	High vs standard dosage fluphenazine HCL in acute schizophrenia. ( Donlon, PT; Meadow, A; Tupin, JP; Wahba, M, 1978)
"Acute dystonia can also be reliably induced in many primate species by neuroleptic treatment with comparable time course, symptomatology and pharmacological characteristics to those observed in man."	2.37	Acute dystonia induced by neuroleptic drugs. ( Jenner, P; Marsden, CD; Rupniak, NM, 1986)
" The clinical effectivity came up to the usual therapy with normal high dosage after 28 days therapy, a somewhat more rapid deliverance of symptoms during the first days remained impressive."	1.26	High dosage treatment with fluphenazine intravenously followed by depot injections in acute schizophrenia. ( Fleischhauer, J, 1980)

Research

Studies (46)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Composite MATRICS Consensus Cognitive Battery Score

Timeframe	Studies, this research(%)	All Research%
pre-1990	38 (82.61)	18.7374
1990's	7 (15.22)	18.2507
2000's	1 (2.17)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
ZIMMERMANN, D	1
BERTONI, M	1
PECHANSKY, I	1
ROITMAN, M	1
CAVALCANTI, O	1
FRIEDMANN, F	1
MOSTARDEIRO, VG	1
PINTO, ES	1
FERREIRA, AC	1
STEIN, R	1
PELLANDA, LE	1
MACHADO, MP	1
Ngui, PW	1
Yesavage, JA	1
Fill, NM	1
Rosenbaum, CP	1
Fleischhauer, J	1
Levinson, DF	3
Simpson, GM	3
Lo, ES	1
Cooper, TB	1
Singh, H	3
Yadalam, K	2
Stephanos, MJ	2
Marder, SR	1
Wirshing, WC	1
Van Putten, T	1
Mintz, J	1
McKenzie, J	1
Johnston-Cronk, K	1
Lebell, M	1
Liberman, RP	1
Robinson, D	1
Woerner, MG	1
Pollack, S	1
Lerner, G	1
Carpenter, WT	1
Buchanan, RW	1
Kirkpatrick, B	1
Breier, AF	1
Subotnik, KL	1
Nuechterlein, KH	1
Ventura, J	1
Goldstein, MJ	3
Rodnick, EH	2
Evans, JR	2
May, PR	2
Donlon, PT	2
Rada, RT	1
Arora, KK	1
Nurnberg, HG	1
Ambrosini, PJ	1
Rifkin, A	1
Quitkin, F	1
Rabiner, CJ	1
Klein, DF	1
Steinberg, MR	1
Obukhov, GA	1
Leff, JP	1
Meadow, A	1
Tupin, JP	1
Wahba, M	1
King, CE	1
Guarneri, M	1
Placidi, GF	1
Cassano, GB	1
Maurer, YA	1
Levenson, AJ	2
Burnett, GB	1
Nottingham, JD	1
Sermas, CE	1
Thornby, JI	1
Pawelkiewicz, K	1
Sekrecki, T	1
Schulz, HD	1
Kluge, HH	1
Korda, W	1
Kube, B	1
Ayd, FJ	1
Johnson, DA	1
Malik, NA	1
Corbett, L	1
Chakos, MH	1
Mayerhoff, DI	1
Loebel, AD	1
Alvir, JM	1
Lieberman, JA	1
Jain, A	1
Silver, P	1
Rupniak, NM	1
Jenner, P	1
Marsden, CD	1
Turns, DM	1
Pary, R	1
Tobias, CR	1
James, WA	1
Altamura, AC	1
Mauri, MC	1
Guercetti, G	1
Cazzullo, CL	1
Sørensen, TT	1
Sørensen, PS	1
Coffman, JA	1
Nasrallah, HA	1
Lyskowski, J	1
McCalley-Whitters, M	1
Dunner, FJ	1
Ropert, R	1
Lévy, L	1
Ropert, M	1
Meltzer, HY	1
Sachar, EJ	1
Frantz, AG	1
Anderson, WH	1
Kuehnle, JC	1
Chien, CP	1
Cole, JO	1
van Praag, HM	1
Dols, LC	1
Grosser, HH	1
Gayral, L	1
Escande, M	1
Fournié, H	1
Perretti, A	1
Schooler, NR	2
Goldberg, SC	2
Boothe, H	1
Rasmussen, OS	1
Pfeiffer, WM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia[NCT00505076]	Phase 2	63 participants (Actual)	Interventional	2007-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The primary outcome measure is the composite score on the Matrics Consensus Cognitive Battery (MCCB). The MCCB composite score is a standardized mean of the seven domain scores. T-scores are standardized to normative data, and have an estimated mean of 50 and SD of 10 in the general healthy population. Data reduction for analysis of neurocognitive testing used the following steps: i) individual neurocognitive test scores at baseline and follow-up were converted to t-scores; ii) t-scores within the pre-specified cognitive domains measured by more than one test were averaged to obtain a domain-specific t-score; and iii) domain-specific t-scores were averaged to create the MCCB composite score. (NCT00505076)
Timeframe: 4 weeks

Schizophrenia Cognition Rating Scale (SCoRS) Score

Intervention	composite score (Mean)
MK-077 8 mg BID	27.9
MK-0777 3 mg BID	31.3
Placebo BID	32.5

The Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity. The SCoRS Interviewer Global Rating of function has a range 1 to 10. Higher ratings indicate greater impairment. (NCT00505076)
Timeframe: 4 Weeks (Baseline to End of Treatment)

UPSA(UCSD Performance-Based Skills Assessment) Summary Score

Intervention	SCoRS Score (Mean)
	Baseline	End of Treatment
MK-077 8 mg BID	4.1	4.0
MK-0777 3 mg BID	4.8	4.6
Placebo BID	3.8	3.6

The UCSD Performance-Based Skills Assessment assessed functional capacity. The UPSA Summary Score has a range from 0 to 120. A higher score indicates less impairment. (NCT00505076)
Timeframe: Baseline and end of treatment, a total of four weeks.

Intervention	UPSA Summary Score (Mean)
	Baseline	End of Treatment
MK-077 8 mg BID	91.7	90.4
MK-0777 3 mg BID	85.0	86.3
Placebo BID	95.0	96.5

Article	Year
Maintenance therapy and schizophrenia. The British journal of psychiatry : the journal of mental science, 1975, Volume: Spec No 9 Topics: Acute Disease; Adult; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Clinic	1975
Acute dystonia induced by neuroleptic drugs. Psychopharmacology, 1986, Volume: 88, Issue:4 Topics: Acute Disease; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease M	1986

Article	Year
Fluphenazine plasma levels, dosage, efficacy, and side effects. The American journal of psychiatry, 1995, Volume: 152, Issue:5 Topics: Acute Disease; Administration, Oral; Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Dose-Re	1995
Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Archives of general psychiatry, 1994, Volume: 51, Issue:4 Topics: Acute Disease; Administration, Oral; Adult; Ambulatory Care; Double-Blind Method; Drug Administratio	1994
Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. Journal of clinical psychopharmacology, 1996, Volume: 16, Issue:2 Topics: Acute Disease; Adult; Clinical Trials as Topic; Combined Modality Therapy; Data Interpretation, Stat	1996
Diazepam treatment of early signs of exacerbation in schizophrenia. The American journal of psychiatry, 1999, Volume: 156, Issue:2 Topics: Acute Disease; Adult; Age of Onset; Anti-Anxiety Agents; Antipsychotic Agents; Diazepam; Drug Admini	1999
Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Archives of general psychiatry, 1977, Volume: 34, Issue:1 Topics: Acute Disease; Administration, Oral; Aftercare; Chronic Disease; Clinical Trials as Topic; Dyskinesi	1977
Drug and family therapy in the aftercare of acute schizophrenics. Archives of general psychiatry, 1978, Volume: 35, Issue:10 Topics: Acute Disease; Adult; Aftercare; Dose-Response Relationship, Drug; Family Therapy; Female; Fluphenaz	1978
Maintenance therapy and schizophrenia. The British journal of psychiatry : the journal of mental science, 1975, Volume: Spec No 9 Topics: Acute Disease; Adult; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Clinic	1975
High vs standard dosage fluphenazine HCL in acute schizophrenia. The Journal of clinical psychiatry, 1978, Volume: 39, Issue:11 Topics: Acute Disease; Adult; Benztropine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doubl	1978
Therapist ratings of achievement of objectives in psychotherapy with acute schizophrenics. Schizophrenia bulletin, 1979, Volume: 5, Issue:1 Topics: Acute Disease; Delayed-Action Preparations; Family Therapy; Female; Fluphenazine; Follow-Up Studies;	1979
Intramuscularly administered fluphenazine HC1 in acute schizophrenia: a retrospective study. Current therapeutic research, clinical and experimental, 1976, Volume: 19, Issue:3 Topics: Acute Disease; Adult; Clinical Trials as Topic; Female; Fluphenazine; Humans; Injections, Intramuscu	1976
Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol. Current therapeutic research, clinical and experimental, 1976, Volume: 20, Issue:5 Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Female; Fluphenazine; Haloperidol; Human	1976
A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta psychiatrica Scandinavica, 1975, Volume: 51, Issue:4 Topics: Acute Disease; Chlorpromazine; Clinical Trials as Topic; Drug Evaluation; Flupenthixol; Fluphenazine	1975
Timing of acute clinical response to fluphenazine. The British journal of psychiatry : the journal of mental science, 1992, Volume: 160 Topics: Acute Disease; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch	1992
Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Archives of general psychiatry, 1990, Volume: 47, Issue:8 Topics: Acute Disease; Akathisia, Drug-Induced; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Dr	1990
Clinical effectiveness of oral and parenteral rapid neuroleptization. The Journal of clinical psychiatry, 1987, Volume: 48, Issue:1 Topics: Acute Disease; Administration, Oral; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Admi	1987
Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study. The American journal of psychiatry, 1973, Volume: 130, Issue:1 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiparkinson Agents; Basal Ganglia Diseases	1973
Fluphenazine enanthate and fluphenazine decanoate: a comparison of their duration of action and motor side effects. The American journal of psychiatry, 1973, Volume: 130, Issue:7 Topics: Acute Disease; Adult; Aged; Chlorpromazine; Clinical Trials as Topic; Esters; Female; Fluphenazine;	1973
Experience of psychiatric management of schizophrenia with fluphenazine decanoate. Diseases of the nervous system, 1970, Volume: 31 Topics: Acute Disease; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Fluphenazine; Humans;	1970
Life history and symptoms in schizophrenia. Severity at hospitalization and response to phenothiazines. Archives of general psychiatry, 1971, Volume: 25, Issue:2 Topics: Acute Disease; Adolescent; Adult; Chlorpromazine; Family; Female; Fluphenazine; Hospitalization; Hum	1971

Article	Year
[CLINICAL OBSERVATIONS ON RESULTS OF ANATENSOL IN PATIENTS WITH ACUTE PSYCHIATRIC DISORDERS]. Revista brasileira de medicina, 1965, Volume: 22 Topics: Acute Disease; Drug Therapy; Fluphenazine; Humans; Mental Disorders	1965
[Clinical significance of depot fluphenazine decanoate in therapy of acute psychotic disorders]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 1983, Volume: 85, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Delayed-Action Preparations; Female; Fluph	1983
Psychopharmacology in the setting of a psychiatric intensive care unit. Psychopharmacology bulletin, 1980, Volume: 16, Issue:2 Topics: Acute Disease; Fluphenazine; Humans; Intensive Care Units; Psychiatric Department, Hospital; Psychot	1980
High dosage treatment with fluphenazine intravenously followed by depot injections in acute schizophrenia. International pharmacopsychiatry, 1980, Volume: 15, Issue:1 Topics: Acute Disease; Adult; Aged; Delayed-Action Preparations; Female; Fluphenazine; Humans; Injections, I	1980
MMPI discriminators of deficit vs. non-deficit recent-onset schizophrenia patients. Psychiatry research, 2000, Mar-06, Volume: 93, Issue:2 Topics: Acute Disease; Adult; Analysis of Variance; Antipsychotic Agents; Case-Control Studies; Female; Flup	2000
Long-acting phenothiazine and social therapy in the community treatment of acute schizophrenics. Psychopharmacology bulletin, 1975, Volume: 11, Issue:4 Topics: Acute Disease; Antipsychotic Agents; Community Mental Health Services; Family Therapy; Fluphenazine;	1975
Depression and the reintegration phase of acute schizophrenia. The American journal of psychiatry, 1976, Volume: 133, Issue:11 Topics: Acute Disease; Adolescent; Adult; Brief Psychiatric Rating Scale; Cognition Disorders; Depression; F	1976
Urinary incontinence in patients receiving neuroleptics. The Journal of clinical psychiatry, 1979, Volume: 40, Issue:6 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Brain; Chlorpromazine; Female; Fluphenazine;	1979
[Prolonged action neuroleptics (review of the foreign literature)]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1975, Volume: 75, Issue:2 Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Child; Chronic Diseas	1975
Depot neuroleptics in the treatment of acute psychoses. L'Encephale, 1979, Volume: 5, Issue:2 Topics: Acute Disease; Adult; Aged; Chlorpromazine; Delayed-Action Preparations; Female; Fluphenazine; Human	1979
[Comparative investigation of action and side effects in intravenous, intramuscular and oral application of fluphenazine dihydrochloride (author's transl)]. Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1979, Volume: 12, Issue:5 Topics: Acute Disease; Administration, Oral; Aging; Female; Fluphenazine; Humans; Injections, Intramuscular;	1979
[Depr;essive syndrome in the course of treatment with Mirenil prolongatum]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1977, Oct-31, Volume: 32, Issue:44 Topics: Acute Disease; Adult; Delayed-Action Preparations; Depression; Female; Fluphenazine; Humans; Neuroti	1977
[Treatment of schizophrenic psychoses with Lyorodin]. Psychiatrie, Neurologie, und medizinische Psychologie, 1977, Volume: 29, Issue:6 Topics: Acute Disease; Chronic Disease; Female; Fluphenazine; Humans; Male; Parkinson Disease, Secondary; Sc	1977
Therapy with injectable fluphenazines. Current psychiatric therapies, 1976, Volume: 16 Topics: Acute Disease; Age Factors; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action	1976
Technique of fluphenazine decanoate therapy in acute schizophrenic illnesses. Diseases of the nervous system, 1975, Volume: 36, Issue:10 Topics: Acute Disease; Ambulatory Care; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluphen	1975
Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacology bulletin, 1992, Volume: 28, Issue:1 Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Female; Fluphenazine; Humans; Incidence; M	1992
Depot neuroleptics for acutely psychotic patients. The American journal of psychiatry, 1987, Volume: 144, Issue:8 Topics: Acute Disease; Antipsychotic Agents; Fluphenazine; Haloperidol; Humans; Psychotic Disorders	1987
Fluphenazine decanoate in acute and maintenance therapy of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 1987, Volume: 11, Issue:5 Topics: Acute Disease; Adult; Female; Fluphenazine; Humans; Long-Term Care; Male; Middle Aged; Psychiatric S	1987
[Repeated acute dystonia following administration of metoclopramide and fluphenazine]. Ugeskrift for laeger, 1988, Mar-14, Volume: 150, Issue:11 Topics: Acute Disease; Adult; Dystonia; Female; Fluphenazine; Humans; Metoclopramide; Recurrence	1988
[Problems of use trials of long-acting tranquilizers in acute psychiatric syndromes]. Annales medico-psychologiques, 1973, Volume: 2, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Fluphenazine; Humans; Male; Middle Aged; Piperid	1973
Serum prolactin levels in newly admitted psychiatric patients. Advances in biochemical psychopharmacology, 1974, Volume: 12, Issue:0 Topics: Acute Disease; Bipolar Disorder; Chicago; Chlorpromazine; Chronic Disease; Depression; Dose-Response	1974
Strategies for the treatment of acute psychosis. JAMA, 1974, Sep-30, Volume: 229, Issue:14 Topics: Acute Disease; Alcohol Amnestic Disorder; Cooperative Behavior; Emergencies; Female; Fluphenazine; H	1974
[Trial of delayed-action neuroleptics in the treatment of acute psychotic conditions]. Annales medico-psychologiques, 1972, Volume: 1, Issue:3 Topics: Acute Disease; Adult; Delayed-Action Preparations; Drug Tolerance; Female; Fluphenazine; Hallucinati	1972
Performance tests in a study of phenothiazines in schizophrenia: caveats and conclusions. Psychopharmacologia, 1972, Volume: 24, Issue:1 Topics: Acute Disease; Ataxia; Behavior; Chlorpromazine; Fluphenazine; Humans; Phenothiazines; Psychiatric S	1972
Fluphenazine enanthate in sesame oil, a depot preparation. Acta psychiatrica Scandinavica, 1970, Volume: 46, Issue:3 Topics: Acute Disease; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Female; Fluphenazine; Huma	1970
[Clinical therapeutic experiences with fluphenazine]. Arzneimittel-Forschung, 1967, Volume: 17, Issue:10 Topics: Acute Disease; Arteriosclerosis; Bipolar Disorder; Catatonia; Chronic Disease; Dementia; Depressive	1967

fluphenazine and Acute Disease